Abstract
Orphan products are associated with increased evidence uncertainty for HTA decision-making. Therefore, HTA agencies have adopted orphan-specific pathways or considerations. However, as usually there is no appropriate comparator, forecasting price of novel orphan products with existing methods is challenging. This research aimed to determine accuracy of using a value-price model to forecast price of an orphan product across different payer archetypes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
